王辉

妇幼代谢相关疾病的危险因素及干预措施研究

1. 国家自然科学基金青年项目：81402741, 2015/01-2017/12，IRAK家族基因与HBV感染相关肝癌遗传易感性及其机制研究，23万，结题，主持。

2. 国家自然科学基金委员会, 国际(地区)合作与交流项目, 72361147521, 营养目标下的食物供给与消费均衡研究, 2024-01-01 至 2028-12-31, 199.6万元, 在研, 参与。

3. 国家卫生健康委科学研究基金, 浙江省卫生健康重大科技计划项目, WKJ-ZJ-2216, 基于结构方程模型解析儿童青少年肥胖的干预效果以及优化干预策略, 2022-01 至 2024-12, 100万元, 在研, 骨干。

4. 北京大学, 青年培育项目, BMU2022PY018, ERLIN1/2-TM6SF2-APOB通路基因变异与膳食因素对儿童NAFLD的分子流行病学研究, 2022-01 至 2022-12, 8万元, 结题, 主持

5. 唐仲英基金(2022-B126), 儿童非酒精性脂肪性肝病的早期干预, 2022-08 至 2025-12, 16万元, 在研, 主持

1. Zhang P, Li L, Fu H, Nur E, Xu D, Wang Y, Gu J, Xu M, Zhou Y, Shen F, Li X, Xing Y, Jin S, Li J, Song Q, Li H, Wen L, Wang H*, Wang HJ*. Effect of an mHealth-assisted multifaceted lifestyle intervention on body-mass index, hepatic fat content and stiffness in children with overweight or obesity: a cluster randomised controlled trial. EClinicalMedicine. 2026. (IF=10.0, Q1)

2. Yang L, Yang S, Wang Y, Hebestreit A, Wang M, Yang Y, Wu Y, Long Y*, Wang H*. Trimester-Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study. Liver Int. 2026. (IF=5.2, Q1)

3. Wang M, Wu Y, Guan H, Gao X, Zhang P, Wang Y, Nur E, Hebestreit A, Wang HJ, Sun L*, Wang H*. Live-Streamed Exercise Intervention in Pregnant Women With MASLD (Live-MASLD): Protocol for a Randomized Controlled Trial. Ann N Y Acad Sci. 2026 (IF=4.8, Q1)

4. Wang Y, Huang DQ, Zhang P, Wang M, Wu Y, Nur E, Li L*, Wang H*. Plasma inflammatory proteome profiles identify MASLD among children with overweight or obesity. Cardiovasc Diabetol. 2025. (IF=10.6, Q1)

5. Wang Y#, Wang H#, Zhang P, Gu J, Shen F, Qiu D, Yang Y, Yang S, Wang M, Wu Y, Nur E, Xu M, Qi L, Hebestreit A, Wang HJ*, Li L*. Tiered school-family-clinic intervention for childhood obesity prevention in China: A nested cluster randomized controlled trial. Med. 2025. (IF=11.4, Q1)

6. Yao MJ, Xing YF, Liu SH, Peng YF, Yang SH, Chen JJ, Zhao JM*, Wang H*. Construction of a community-based primary screening and hospital-based confirmatory screening pathway in pediatric nonalcoholic fatty liver disease. World J Gastroenterol. 2025. (IF=5.4, Q1)

7. Liu Y, Wang Y, Xing Y, Wolters M, Shi D, Zhang P, Dang J, Chen Z, Cai S, Wang Y, Liu J, Wang X, Zhou H, Xu M, Guo L, Li Y, Song J, Li J, Dong Y, Cui Y, Hu P, Hebestreit A, Wang HJ, Li L, Ma J, Yeo YH, Wang H*, Song Y*. Establish a noninvasive model to screen metabolic dysfunction-associated steatotic liver disease in children aged 6-14 years in China and its applications in high-obesity-risk countries and regions. Lancet Reg Health West Pac. 2024. (IF=8.1, Q1)

8. Xing Y, Gao X, Li Q, Li X, Wang Y, Yang Y, Yang S, Lau PWC, Zeng Q*, Wang H*. Associations between exposure to ambient particulate matter and advanced liver fibrosis in Chinese MAFLD patients. J Hazard Mater. 2023. (IF=11.3, Q1)

9. Xing Y, Zhang P, Li X, Jin S, Xu M, Jia J, Wang HJ, Li L*, Wang H*. New predictive models and indices for screening MAFLD in school-aged overweight/obese children. Eur J Pediatr. 2023. (IF=2.6, Q1)

10. Wang H#, El Maadidi S#, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Löffler MW, Wiese M, Pichulik T, Müllhaupt B, Semela D, Dufour JF, Bochud PY, Bowie AG, Kalinke U, Berg T*, Weber AN*; East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology. 2015. (IF=11.7, Q1)